Andrew Pang

Andrew Pang is a Managing Director of Ally Bridge Group and focuses on medical devices investments and private equity transactions. He joined the team led by Frank Yu in 2011 and has since played an important role in underwriting and executing notable transactions including the take-private of WuXi Pharmatech and Shandong Luoxin Pharmaceutical as well as the Series C investment in GRAIL, Inc. Before joining ABG, Mr. Pang worked at InterLeader, a family-office investment group in Hong Kong, focusing on private equity transactions. Prior to returning to Hong Kong, Mr. Pang worked at Bank of America in London, where he worked on European leveraged buyout transactions. Mr. Pang has developed excellent deal execution skills and cross-border investment experience. Mr. Pang holds a BA in Mathematics and Computer Science from the University of Cambridge where he graduated with first class honors.